Three Chinese pharmaceutical intermediate makers target global drug supply chains

Three Chinese manufacturers are positioning themselves as key suppliers of pharmaceutical intermediates for cancer, antiviral and chronic disease drugs as global demand rises. The companies differ in scale and specialization, but all are betting on tighter quality control, regulatory compliance and supply-chain resilience.

Why it matters: - Global drug developers are looking for more reliable sources of pharmaceutical intermediates as demand rises for cost-effective, high-quality inputs used to make APIs. - Supply-chain resilience matters more as targeted therapies and complex drug programs require tighter purity control, better documentation and faster turnaround. - Chinese manufacturers already account for more than 30% of global intermediate supply, making their capabilities a major factor in worldwide drug development.

What happened: - The article highlights three Chinese pharmaceutical intermediate manufacturers: Haohong (Qihe) Pharmaceutical Technology Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd. and CSPC Pharmaceutical Group Limited. - Haohong is based in Shandong Province and was established in 2021. - Huahai was founded in 1998 and is headquartered in Linhai, Zhejiang. - CSPC was founded in 1938 and is headquartered in Shijiazhuang, Hebei. - The companies are presented as suppliers for anti-cancer, antiviral, cardiovascular, central nervous system and chronic disease drug pipelines.

The details: - Haohong specializes in high-grade active pharmaceutical intermediates and custom synthesis. - Haohong employs about 75 staff and runs a 3,000-square-meter manufacturing facility with annual production capacity of 1,000 tons. - Export sales account for 40% of Haohong revenue, with products shipped to the U.S., Europe, Japan, India and Bangladesh. - Haohong holds ISO 9001:2015 certification and received Technology-based Small and Medium-sized Enterprise recognition in 2024 and Innovative Small and Medium-sized Enterprise of Shandong Province recognition in 2025. - Haohong’s R&D team includes 30 engineers and supports custom synthesis from gram scale to hundreds of kilograms. - Haohong’s Liaocheng production base has 30 reactors ranging from 3,000 to 5,000 liters. - Haohong focuses on intermediates used in Apalutamide, Abemaciclib and Alectinib. - Haohong says its products reach ultra-high purity of at least 98%, with strict impurity control, batch-to-batch consistency and technical documentation aligned with ICH and GMP standards. - Haohong holds utility model patents for equipment including a waste gas absorption device and a gas chromatography detection system. - Huahai is one of China’s largest API and intermediate manufacturers and specializes in cardiovascular, central nervous system and anti-cancer drugs. - Huahai operates multiple FDA- and EMA-approved facilities and exports to more than 50 countries. - Huahai’s vertically integrated supply chain supports production capacity above 5,000 tons per year for certain intermediates. - Huahai has more than 100 ANDAs in its regulatory dossier library and a market capitalization above $3 billion. - CSPC is a major Chinese pharmaceutical conglomerate with more than 20,000 employees and annual revenue above $4 billion. - CSPC manufactures chemical intermediates, APIs and finished formulations, including oncology precursors for lenvatinib and olaparib. - CSPC uses proprietary continuous flow chemistry technology and can scale from laboratory to commercial production quickly. - CSPC holds multiple patents on synthesis routes and supplies multinational pharmaceutical companies with clinical trial materials.

Between the lines: - Haohong is positioning itself as the agile, high-purity specialist for customers that need custom intermediates rather than massive volume. - Huahai and CSPC compete more on scale, regulatory reach and brand recognition. - Internal comparison data cited in the source says Haohong’s product purity averages 0.02% above industry peers and batch stability is 10% above the industry average. - A Shanghai-based pharmaceutical supply chain analyst said specialized manufacturers can offer better customization and faster response times than large volume players. - The shift toward antibody-drug conjugates and protein degraders is increasing demand for intermediates with controlled chiral and steric properties.

What’s next: - Haohong plans to expand reactor capacity and pursue additional certifications. - Huahai is investing in continuous manufacturing platforms. - CSPC is accelerating its innovative drug pipeline, which should lift demand for proprietary intermediates. - The competitive landscape in China is still fragmented, but companies with technical depth and international traceability appear positioned to gain more business.

The bottom line: - The three companies illustrate how China’s intermediate makers are moving from commodity supply toward specialized, globally integrated drug-development support.